Candidate Compounds Covid19

(Unterschied zwischen Versionen)
Wechseln zu: Navigation, Suche
K
(21 dazwischenliegende Versionen von einem Benutzer werden nicht angezeigt)
Zeile 1: Zeile 1:
 
{{pnc}}
 
{{pnc}}
 +
{{ft|P}}
 +
...so calm down and enjoy the progress of immediate translational medicine:
 +
A concept of curative retargeting has been found by cellular lockdown with kinase inhibitors from the oncologic pharmacopoiea.
 +
This means, virus replication can be stalled to zero w/o need of develpoment of new substances. There is no need for world
 +
vaccination anymore. The virus needs permissible cells, and most perimissible is phosphotyrosine on its own compnents.
 +
Paper is (not yet in PubMed) :
  
−
current items will be put into the subsections.
+
*'''[https://www.sciencedirect.com/science/article/pii/S1097276520305499?via%3Dihub Growth factor receptor signaling inhibition prevents SARS-CoV-2 replication at Mol Cell 2020/08/11]'''
 +
credentials to [https://web.de/magazine/news/coronavirus/coronavirus-blockade-zellulaerer-kommunikation-forscher-stoppen-vermehrung-sars-cov-2-35045170 Marinus Brandl] who told us about it today.
 +
based on e.g.
 +
 
 +
{{ttp|p=32408336|t=2020. Proteomics of SARS-CoV-2-infected host cells reveals therapy targets |pdf=|usr=}}
 +
 
 +
=======================================================================================
 +
 
 +
COVID19 is now a CURABLE disease !!!
 +
 
 +
=======================================================================================
  
 
*[[reviews on covid drug development]]  
 
*[[reviews on covid drug development]]  
Zeile 26: Zeile 42:
 
*[[Target Complement system]]
 
*[[Target Complement system]]
 
*[[Target Extracellular traps]]
 
*[[Target Extracellular traps]]
 +
*[[Caplacizumab]] vWF(TTP)
 +
*[[Target Neurophils]]
 +
*[[Target Mast cells]] and kinins
 
*[[TGF beta]]
 
*[[TGF beta]]
 +
*[[Immunosuppressants]]
 
*[[Anticoagulant in covid19]]
 
*[[Anticoagulant in covid19]]
 
*[[Antioxidants]]
 
*[[Antioxidants]]
 +
*[[HIF-EPO-Iron]]
 
*[[Stem cells]]
 
*[[Stem cells]]
 
*[[MDSC cells]]
 
*[[MDSC cells]]
 
*[[Interferons]]
 
*[[Interferons]]
 +
*[[cAMP cGMP PDE NO]]
 +
*[[TRPV* channels]]
 +
*[[Retinoids]]
 +
*[[Protease inhibitors]]
 +
*[[Tyrosine kinase inhibitors]]
 +
*[[Antineoplastic agents, traditional]]
 +
*[[Mouthrinses]]
 +
*[[Adenosinergic signaling]]
 +
*[[Purinergic signaling]]
 +
*[[Nicotinergic signaling]]
  
  
 
*[[other single compounds]]
 
*[[other single compounds]]
−
*[[Retargeted single compounds]]
+
*[[Retargeted Psychopharm]]
 
*[[Hydroxychloroquine]]  
 
*[[Hydroxychloroquine]]  
 
*
 
*
 
*[[Target ACE2, Spike protein]]
 
*[[Target ACE2, Spike protein]]
 
*[[Target TMPRSS2, Spike protein]] ''any other covid targed herein''
 
*[[Target TMPRSS2, Spike protein]] ''any other covid targed herein''
 +
*[[Aprotinin]] protease inh bradykinin synth. inh.
 
*[[other antiviral compounds]]
 
*[[other antiviral compounds]]
 
*[[AV Remdesivir]]
 
*[[AV Remdesivir]]
Zeile 47: Zeile 79:
 
*[[AV Favipiravir]]
 
*[[AV Favipiravir]]
  
 +
*[[Antibiotics]]
  
  
Zeile 53: Zeile 86:
 
*[[Anorganic nutrients Selenium]]
 
*[[Anorganic nutrients Selenium]]
 
*[[Anorganic nutrients Zinc]]
 
*[[Anorganic nutrients Zinc]]
 +
*[[Anorganic nutrients Lithium]]
 +
*[[Anorganic nutrients Copper]]
 +
*[[Anorganic nutrients Bismuth]]
 
*[[Nutrition, general]]
 
*[[Nutrition, general]]
 
*[[Exercise, Vibration]]
 
*[[Exercise, Vibration]]
Zeile 63: Zeile 99:
 
*[[Antidiabetic compounds, any]]
 
*[[Antidiabetic compounds, any]]
 
*[[RSP - On RAS drugs]]
 
*[[RSP - On RAS drugs]]
 +
*[[RSP - On NSAIDs]]
  
 
*[[Reconvalescent blood products, Passive vaccine]]  
 
*[[Reconvalescent blood products, Passive vaccine]]  
Zeile 72: Zeile 109:
 
*[[Active vaccine]]  
 
*[[Active vaccine]]  
  
−
===-rest-===
+
*[[Treatment other concepts]]
−
{{tp|p=32458400|t=2020. Implications for Neuromodulation Therapy to Control Inflammation and Related Organ Dysfunction in COVID-19.|pdf=|usr=008}}
+
----
−
{{tp|p=32401611|t=2020. The pulmonary-proteoliposome as a new therapeutic approach for Coronaviruses.|pdf=|usr=008}}
+
−
{{tp|p=32413736|t=2020. Towards treatment planning of COVID-19: Rationale and hypothesis for the use of multiple immunosuppressive agents: Anti-antibodies, immunoglobulins, and corticosteroids.|pdf=|usr=008}}
+
−
{{tp|p=32534188|t=2020. Severe Acute Respiratory Syndrome Coronavirus -2 (SARS-CoV-2): A global pandemic and treatments strategies.|pdf=|usr=008}}
+
−
{{tp|p=32531935|t=2020. Chronic Inflammation in the Context of Everyday Life: Dietary Changes as Mitigating Factors.|pdf=|usr=008}}
+
−
{{tp|p=32384202|t=2020. Home-based training strategy to maintain muscle function in older adults with diabetes during COVID-19 confinement.|pdf=|usr=008}}
+
−
{{tp|p=32315803|t=2020. Preliminary therapeutic drug monitoring data of beta-lactams in critically ill patients with SARS-CoV-2 infection.|pdf=|usr=008}}
+
−
{{tp|p=32519894|t=2020. Heparin as a Therapy for COVID-19: Current Evidence and Future Possibilities.|pdf=|usr=008}}
+
−
{{tp|p=32345532|t=2020. Response to: Bioactive Lipids and Coronavirus (COVID-19)-further Discussion.|pdf=|usr=008}}
+
−
{{tp|p=32399093|t=2020. Lipid-lowering therapy and renin-angiotensin-aldosterone system inhibitors in the era of the COVID-19 pandemic.|pdf=|usr=008}}
+
−
{{tp|p=32532623|t=2020. Fighting COVID-19: A quick review of diagnoses, therapies, and vaccines.|pdf=|usr=008}}
+
−
{{tp|p=32401215|t=2020. Telehealth Home Support During COVID-19 Confinement for Community-Dwelling Older Adults With Mild Cognitive Impairment or Mild Dementia: Survey Study.|pdf=|usr=008}}
+
−
{{tp|p=32468385|t=2020. Musings on the current state of COVID-19 modeling and reporting.|pdf=|usr=008}}
+
−
{{tp|p=32523144|t=2020. Protocolo para la prevencion de arritmias ventriculares debido al tratamiento en pacientes con COVID-19.|pdf=|usr=008}}
+
−
{{tp|p=32516380|t=2020. Covid-19's Impact on Podiatry in Chicago's Largest Public Hospital.|pdf=|usr=008}}
+
−
{{tp|p=32390307|t=2020. Practical tips for using masks in the COVID-19 pandemic.|pdf=|usr=008}}
+
−
{{tp|p=32358890|t=2020. Cutaneous side-effects of the potential COVID-19 drugs.|pdf=|usr=008}}
+
−
{{tp|p=32475694|t=2020. Reflexions autour d'une evolution favorable d'une COVID-19 chez un patient presentant une schizophrenie resistante et sous une association clozapine et paliperidone palmitate.|pdf=|usr=008}}
+
−
{{tp|p=32406749|t=2020. Oncology clinical trials in the time of COVID-19: how a pandemic can revolutionize patients' care.|pdf=|usr=008}}
+
−
{{tp|p=32535509|t=2020. COVID-19, interferons, and depression: A commentary.|pdf=|usr=008}}
+
−
{{tp|p=32496248|t=2020. Effectiveness of preventive measures against COVID-19: A systematic review of In Silico modeling studies in indian context.|pdf=|usr=007}}
+
−
{{tp|p=32496246|t=2020. Impact of nonpharmacological interventions on COVID-19 transmission dynamics in India.|pdf=|usr=007}}
+
−
{{tp|p=32429572|t=2020. The Role of Lipid Metabolism in COVID-19 Virus Infection and as a Drug Target.|pdf=|usr=007}}
+
−
{{tp|p=32408699|t=2020. Essential Oils as Antiviral Agents. Potential of Essential Oils to Treat SARS-CoV-2 Infection: An In-Silico Investigation.|pdf=|usr=007}}
+
−
{{tp|p=32457038|t=2020. Potential COVID-19 therapeutics from a rare disease: Weaponizing lipid dysregulation to combat viral infectivity.|pdf=|usr=007}}
+
−
{{tp|p=32423974|t=2020. COVID-19 and Rheumatology patients on immunomodulatory therapy - can we extrapolate data from previous viral pandemics?|pdf=|usr=007}}
+
−
{{tp|p=32475104|t=2020. Coronavirus Disease 2019 Presenting as Conjunctivitis.|pdf=|usr=007}}
+
−
{{tp|p=32418757|t=2020. Pancreatic cancer: Does a short course of carbon ion radiotherapy worth during COVID-19 outbreak?|pdf=|usr=007}}
+
−
{{tp|p=32505040|t=2020. The end of 'cordon sanitaire' in Wuhan: the role of non-pharmaceutical interventions against COVID-19.|pdf=|usr=007}}
+
−
{{tp|p=32472939|t=2020. Assessing the impact of non-pharmaceutical interventions on SARS-CoV-2 transmission in Switzerland.|pdf=|usr=007}}
+
−
{{tp|p=32491981|t=2020. Nonpharmaceutical Measures for Pandemic Influenza in Nonhealthcare Settings-International Travel-Related Measures.|pdf=|usr=007}}
+
−
{{tp|p=32487283|t=2020. Effect of Nonpharmaceutical Interventions on Transmission of Severe Acute Respiratory Syndrome Coronavirus 2, South Korea, 2020.|pdf=|usr=007}}
+
−
{{tp|p=32460209|t=2020. The effect of potential therapeutic agents on QT interval in patients with COVID-19 Infection: The importance of close monitoring and correction of electrolytes.|pdf=|usr=007}}
+
−
{{tp|p=32487990|t=2020. Modeling mitigation of influenza epidemics by baloxavir.|pdf=|usr=007}}
+
−
{{tp|p=32512579|t=2020. Estimating the effects of non-pharmaceutical interventions on COVID-19 in Europe.|pdf=|usr=007}}
+
−
{{tp|p=32116200|t=2020. COVID-19: Perspectives on the Potential Novel Global Threat.|pdf=|usr=007}}
+
−
{{tp|p=32463459|t=2020. Prescription Fill Patterns for Commonly Used Drugs During the COVID-19 Pandemic in the United States.|pdf=|usr=007}}
+
−
{{tp|p=32498081|t=2020. Conducting clinical trials in heart failure during (and after) the COVID-19 pandemic: an Expert Consensus Position Paper from the Heart Failure Association (HFA) of the European Society of Cardiology (ESC).|pdf=|usr=007}}
+
−
{{tp|p=32464736|t=2020. A simulation training course for family medicine residents in China managing COVID-19.|pdf=|usr=007}}
+
−
{{tp|p=32442317|t=2020. The case for Chronotherapy in COVID-19 induced Acute Respiratory Distress Syndrome (ARDS).|pdf=|usr=007}}
+
−
{{tp|p=32403134|t=2020. Combination dose-escalated hydroxyurea and transfusion: an approach to conserve blood during the COVID-19 pandemic.|pdf=|usr=007}}
+
−
{{tp|p=32407551|t=2020. Interrogation of the safety and efficacy of home-use light-based devices.|pdf=|usr=007}}
+
−
{{tp|p=32429705|t=2020. COVID-19 and Nutrition: The Need for Initiatives to Promote Healthy Eating and Prevent Obesity in Childhood.|pdf=|usr=007}}
+
−
{{tp|p=32510719|t=2020. Intramatricial methotrexate for treatment of resistant acrodermatitis continua of Hallopeau: an alterative in Covid-19.|pdf=|usr=007}}
+
−
{{tp|p=32500633|t=2020. "Thinking outside the box in COVID-19 era"-Application of Modified Aerosol Box in Dermatology.|pdf=|usr=007}}
+
−
{{tp|p=32229705|t=2020. Geroprotective and senoremediative strategies to reduce the comorbidity, infection rates, severity, and lethality in gerophilic and gerolavic infections |pdf=|usr=}}
+
−
{{tp|p=32276453|t=2020. Exploring the Relevance of Senotherapeutics for the Current SARS-CoV-2 Emergency  and Similar Future Global Health Threats |pdf=|usr=}}
+
−
{{tp|p=32325124|t=ä. Vaporization, bioactive formulations and a marine natural product: different perspectives on antivirals |pdf=|usr=}}
+
−
{{tp|p=32312129|t=2020. The role of additive manufacturing and antimicrobial polymers in the COVID-19 pandemic |pdf=|usr=}}
+
−
{{tp|p=32336674|t=ä. COVID-19 Emergency Responders in FDA?s Center for Drug Evaluation and Research |pdf=|usr=}}
+
−
{{tp|p=32356251|t=ä. Medical Toxicology and COVID-19: Our Role in a Pandemic |pdf=|usr=}}
+
−
{{tp|p=32243778|t=2020. Ensuring global access to COVID-19 vaccines |pdf=|usr=}}
+
−
{{tp|p=32247324|t=2020. Global coalition to accelerate COVID-19 clinical research in resource-limited settings |pdf=|usr=}}
+
−
{{tp|p=32272857|t=2020. Role of Tissue Engineering in COVID-19 and Future Viral Outbreaks |pdf=|usr=}}
+
−
{{tp|p=C7190525|t=2020. Adjunct Immunotherapies for the Management of Severely Ill COVID-19 Patients |pdf=|usr=}}
+
−
{{tp|p=32129977|t=2020. Cell-Membrane-Mimicking Nanodecoys against Infectious Diseases |pdf=|usr=}}
+
−
{{tp|p=29115746|t=2018. Progress Toward the Clinical Translation of Bioinspired Peptide and Protein Assemblies |pdf=|usr=}}
+
−
{{tp|p=29717819|t=2018. Recent Advances in the Development of Antimicrobial Nanoparticles for Combating Resistant Pathogens |pdf=|usr=}}
+
−
{{tp|p=C7194243|t=ä. Coronavirus Disease 2019 (COVID-19) Spread and Pharmacovigilance Implications: Expert Opinion |pdf=|usr=}}
+
−
{{tp|p=32383008|t=ä. The Role of Pharmacovigilance and ISoP During the Global COVID-19 Pandemic |pdf=|usr=}}
+
−
{{tp|p=32380052|t=2020. Granulocyte-targeted therapies for airway diseases |pdf=|usr=}}
+
−
{{tp|p=32452420|t=2020. Antiviral activity of lycorine against Zika virus in vivo and in vitro |pdf=|usr=}}
+
−
 
+
−
===009===
+
−
 
+
−
 
+
−
{{tp|p=32535032|t=2020. Vitamin D Receptor stimulation to reduce Acute Respiratory Distress Syndrome (ARDS) in patients with Coronavirus SARS-CoV-2 infections: Revised Ms SBMB 2020_166.|pdf=|usr=009}}
+
−
{{tp|p=32435607|t=2020. Potential Role of ACE2 in Coronavirus Disease 2019 (COVID-19) Prevention and Management.|pdf=|usr=009}}
+
−
{{tp|p=32423449|t=2020. Rationale for the clinical use of adipose-derived mesenchymal stem cells for COVID-19 patients.|pdf=|usr=009}}
+
−
{{tp|p=32493510|t=2020. SARS-CoV-2 SPIKE PROTEIN: an optimal immunological target for vaccines.|pdf=|usr=009}}
+
−
{{tp|p=32405423|t=2020. Minimum costs to manufacture new treatments for COVID-19.|pdf=|usr=009}}
+
−
{{tp|p=32405422|t=2020. Review of safety and minimum pricing of nitazoxanide for potential treatment of COVID-19.|pdf=|usr=009}}
+
−
{{tp|p=32405421|t=2020. A review of the safety of favipiravir - a potential treatment in the COVID-19 pandemic?|pdf=|usr=009}}
+
−
{{tp|p=32401274|t=2020. SARS-CoV-2 Rates in BCG-Vaccinated and Unvaccinated Young Adults.|pdf=|usr=009}}
+
−
{{tp|p=32392282|t=2020. Association of Treatment With Hydroxychloroquine or Azithromycin With In-Hospital Mortality in Patients With COVID-19 in New York State.|pdf=|usr=009}}
+
−
{{tp|p=32501511|t=2020. Simulated Assessment of Pharmacokinetically Guided Dosing for Investigational Treatments of Pediatric Patients With Coronavirus Disease 2019.|pdf=|usr=009}}
+
−
{{tp|p=32530438|t=2020. New (re)Purpose for an old drug: purinergic receptor blockade may extinguish the COVID-19 thrombo-inflammatory firestorm.|pdf=|usr=009}}
+
−
{{tp|p=32459647|t=2020. Intra-Rater and Inter-Rater Reliability of Tongue Coating Diagnosis in Traditional Chinese Medicine Using Smartphones: Quasi-Delphi Study.|pdf=|usr=009}}
+
−
{{tp|p=32384188|t=2020. Parenteral Fish-Oil Emulsions in Critically Ill COVID-19 Emulsions.|pdf=|usr=009}}
+
−
{{tp|p=32533592|t=2020. Pharmacist's perspective on HCQ treatment of COVID-19.|pdf=|usr=009}}
+
−
{{tp|p=32460458|t=2020. In vitro activity of lopinavir/ritonavir and hydroxychloroquine against severe acute respiratory syndrome coronavirus 2 at concentrations achievable by usual doses.|pdf=|usr=009}}
+
−
{{tp|p=32401715|t=2020. Triple combination of interferon beta-1b, lopinavir-ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: an open-label, randomised, phase 2 trial.|pdf=|usr=009}}
+
−
{{tp|p=32401712|t=2020. Interferon beta-1b for COVID-19.|pdf=|usr=009}}
+
−
{{tp|p=32410758|t=2020. Consider pregnancy in COVID-19 therapeutic drug and vaccine trials.|pdf=|usr=009}}
+
−
{{tp|p=32450109|t=2020. Chloroquine or hydroxychloroquine for COVID-19: why might they be hazardous?|pdf=|usr=009}}
+
−
{{tp|p=32464115|t=2020. Caution against corticosteroid-based COVID-19 treatment.|pdf=|usr=009}}
+
−
{{tp|p=32473680|t=2020. The starting line for COVID-19 vaccine development.|pdf=|usr=009}}
+
−
{{tp|p=32450106|t=2020. Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial.|pdf=|usr=009}}
+
−
{{tp|p=32445630|t=2020. Vitamin-D and COVID-19: do deficient risk a poorer outcome?|pdf=|usr=009}}
+
−
{{tp|p=32450054|t=2020. Hydroxychloroquine prophylaxis for high-risk COVID-19 contacts in India: a prudent approach.|pdf=|usr=009}}
+
−
{{tp|p=32473139|t=2020. Death threats after a trial on chloroquine for COVID-19.|pdf=|usr=009}}
+
−
{{tp|p=32518920|t=2020. Caution and clarity required in the use of chloroquine for COVID-19.|pdf=|usr=009}}
+
−
{{tp|p=32501454|t=2020. Interleukin-1 blockade with high-dose anakinra in patients with COVID-19, acute respiratory distress syndrome, and hyperinflammation: a retrospective cohort study.|pdf=|usr=009}}
+
−
{{tp|p=32518419|t=2020. The Janus kinase 1/2 inhibitor ruxolitinib in COVID-19 with severe systemic hyperinflammation.|pdf=|usr=009}}
+
−
{{tp|p=32528040|t=2020. Holding CoVID in check through JAK? The MPN-approved compound ruxolitinib as a potential strategy to treat SARS-CoV-2 induced systemic hyperinflammation.|pdf=|usr=009}}
+
−
{{tp|p=32535078|t=2020. Vaccination strategies to combat novel corona virus SARS-CoV-2.|pdf=|usr=009}}
+
−
{{tp|p=32535080|t=2020. Virtual screening, ADME/Tox predictions and the drug repurposing concept for future use of old drugs against the COVID-19.|pdf=|usr=009}}
+
−
{{tp|p=32497632|t=2020. Potential therapeutic targets for combating SARS-CoV-2: Drug repurposing, clinical trials and recent advancements.|pdf=|usr=009}}
+
−
{{tp|p=32454157|t=2020. Crosstalk between endoplasmic reticulum stress and anti-viral activities: A novel therapeutic target for COVID-19.|pdf=|usr=009}}
+
−
{{tp|p=32450171|t=2020. Coronaviruses pandemics: Can neutralizing antibodies help?|pdf=|usr=009}}
+
−
{{tp|p=32450166|t=2020. Unravelling lead antiviral phytochemicals for the inhibition of SARS-CoV-2 M(pro) enzyme through in silico approach.|pdf=|usr=009}}
+
−
{{tp|p=32422305|t=2020. Lungs as target of COVID-19 infection: Protective common molecular mechanisms of vitamin D and melatonin as a new potential synergistic treatment.|pdf=|usr=009}}
+
−
{{tp|p=32418894|t=2020. A systematic review on use of aminoquinolines for the therapeutic management of COVID-19: Efficacy, safety and clinical trials.|pdf=|usr=009}}
+
−
{{tp|p=32478465|t=2020. First case of drug-induced liver injury associated with the use of tocilizumab in a patient with COVID-19.|pdf=|usr=009}}
+
−
{{tp|p=32532461|t=2020. Eficacia de los pulsos de corticoides en pacientes con sindrome de liberacion de citocinas inducido por infeccion por SARS-CoV-2.|pdf=|usr=009}}
+
−
{{tp|p=32425245|t=2020. Hidroxicloroquina en el tratamiento del COVID-19: como utilizarla a la espera de evidencia cientifica concluyente.|pdf=|usr=009}}
+
−
{{tp|p=32416415|t=2020. Etoposide-based therapy for severe forms of COVID-19.|pdf=|usr=009}}
+
−
{{tp|p=32516655|t=2020. Pulmonary delivery of nanostructured lipid carriers for effective repurposing of salinomycin as an antiviral agent.|pdf=|usr=009}}
+
−
{{tp|p=32504923|t=2020. N-Acetylcysteine: A potential therapeutic agent for SARS-CoV-2.|pdf=|usr=009}}
+
−
{{tp|p=32485316|t=2020. Pentoxifylline and complicated COVID-19: A pathophysiologically based treatment proposal.|pdf=|usr=009}}
+
−
{{tp|p=32498007|t=2020. Immunopharmacological management of COVID-19: Potential therapeutic role of valproic acid.|pdf=|usr=009}}
+
−
{{tp|p=32492562|t=2020. The association between obesity and poor outcome after COVID-19 indicates a potential therapeutic role for montelukast.|pdf=|usr=009}}
+
−
{{tp|p=32480250|t=2020. Protective effects of vaccinations and endemic infections on COVID-19: A hypothesis.|pdf=|usr=009}}
+
−
{{tp|p=32464491|t=2020. Selenium supplementation in the prevention of coronavirus infections (COVID-19).|pdf=|usr=009}}
+
−
{{tp|p=32526511|t=2020. A potential role for cyclophosphamide in the mitigation of acute respiratory distress syndrome among patients with SARS-CoV-2.|pdf=|usr=009}}
+
−
{{tp|p=32473509|t=2020. Zinc Iodide in combination with Dimethyl Sulfoxide for treatment of SARS-CoV-2 and other viral infections.|pdf=|usr=009}}
+
−
{{tp|p=32470789|t=2020. Survival of COVID-19 patients requires precise immune regulation: The hypothetical immunoprotective role of nicotinic agonists.|pdf=|usr=009}}
+
−
{{tp|p=32534175|t=2020. Three novel prevention, diagnostic, and treatment options for COVID-19 urgently necessitating controlled randomized trials.|pdf=|usr=009}}
+
−
{{tp|p=32464494|t=2020. Homocysteine as a potential predictor of cardiovascular risk in patients with COVID-19.|pdf=|usr=009}}
+
−
{{tp|p=32526507|t=2020. Use of hydroxychloroquine and interferon alpha-2b for the prophylaxis of COVID-19.|pdf=|usr=009}}
+
−
{{tp|p=32464493|t=2020. Hypoxia inducible factor-1 protects against COVID-19: A hypothesis.|pdf=|usr=009}}
+
−
{{tp|p=32464492|t=2020. Can moderate intensity aerobic exercise be an effective and valuable therapy in preventing and controlling the pandemic of COVID-19?|pdf=|usr=009}}
+
−
{{tp|p=32460208|t=2020. Sodium chromo-glycate and palmitoylethanolamide: A possible strategy to treat mast cell-induced lung inflammation in COVID-19.|pdf=|usr=009}}
+
−
{{tp|p=32425307|t=2020. Mesenchymal Stem Cells -Bridge Catalyst Between Innte And Adaptive Immunity In Covid 19.|pdf=|usr=009}}
+
−
{{tp|p=32425306|t=2020. Protective potential of Expectorants against COVID-19.|pdf=|usr=009}}
+
−
{{tp|p=32425303|t=2020. Bioactive compounds with possible inhibitory activity of Angiotensin-Converting Enzyme-II; a gate to manage and prevent COVID-19.|pdf=|usr=009}}
+
−
{{tp|p=32428811|t=2020. Exercise as medicine for COVID-19: An ACE in the hole?|pdf=|usr=009}}
+
−
{{tp|p=32416408|t=2020. As a potential treatment of COVID-19: Montelukast.|pdf=|usr=009}}
+
−
{{tp|p=32413699|t=2020. Lithium chloride combination with rapamycin for the treatment of COVID-19 pneumonia.|pdf=|usr=009}}
+
−
{{tp|p=32531538|t=2020. Is hesperidin essential for prophylaxis and treatment of COVID-19 Infection?|pdf=|usr=009}}
+
−
{{tp|p=32531537|t=2020. RAGE receptor: May be a potential inflammatory mediator for SARS-COV-2 infection?|pdf=|usr=009}}
+
−
{{tp|p=32516733|t=2020. B-cell engineering: A promising approach towards vaccine development for COVID-19.|pdf=|usr=009}}
+
−
{{tp|p=32535456|t=2020. Natural RNA dependent RNA polymerase inhibitors: Molecular docking studies of some biologically active alkaloids of Argemone mexicana.|pdf=|usr=009}}
+
−
{{tp|p=32534337|t=2020. Diacerein: A potential multi-target therapeutic drug for COVID-19.|pdf=|usr=009}}
+
−
{{tp|p=32505075|t=2020. Fighting against frailty and sarcopenia - As well as COVID-19?|pdf=|usr=009}}
+
−
{{tp|p=32505072|t=2020. COVID-19 and picotechnology: Potential opportunities.|pdf=|usr=009}}
+
−
{{tp|p=32505069|t=2020. Hydrogen peroxide and viral infections: A literature review with research hypothesis definition in relation to the current covid-19 pandemic.|pdf=|usr=009}}
+
−
{{tp|p=32400020|t=2020. COVID-19 and implications for thiopurine use.|pdf=|usr=009}}
+
−
{{tp|p=32395220|t=2020. SARS-CoV-2 (COVID-19) and Chronic Myeloid Leukemia (CML): a Case Report and Review of ABL Kinase Involvement in Viral Infection.|pdf=|usr=009}}
+
−
{{tp|p=32470350|t=2020. Commentary: Myths and facts on vitamin D amidst the COVID-19 pandemic.|pdf=|usr=009}}
+
−
{{tp|p=32497535|t=2020. Commentary: Phosphodiesterase 4 inhibitors as potential adjunct treatment targeting the cytokine storm in COVID-19.|pdf=|usr=009}}
+
−
{{tp|p=32418885|t=2020. Commentary: Could iron chelators prove to be useful as an adjunct to COVID-19 Treatment Regimens?|pdf=|usr=009}}
+
−
{{tp|p=32473390|t=2020. A review of South Indian medicinal plant has the ability to combat against deadly viruses along with COVID-19?|pdf=|usr=009}}
+
−
{{tp|p=32437926|t=2020. From SARS-CoV to SARS-CoV-2: safety and broad-spectrum are important for coronavirus vaccine development.|pdf=|usr=009}}
+
−
{{tp|p=32445881|t=2020. Arbidol/IFN-alpha2b therapy for patients with corona virus disease 2019: a retrospective multicenter cohort study.|pdf=|usr=009}}
+
−
{{tp|p=32442649|t=2020. Plant Solutions for the COVID-19 Pandemic and Beyond: Historical Reflections and Future Perspectives.|pdf=|usr=009}}
+
−
{{tp|p=32533920|t=2020. The Improbability of the Rapid Development of a Vaccine for SARS-CoV-2.|pdf=|usr=009}}
+
−
{{tp|p=32404512|t=2020. Can Unconventional Immunomodulatory Agents Help Alleviate COVID-19 Symptoms and Severity?|pdf=|usr=009}}
+
−
{{tp|p=32445440|t=2020. Remdesivir for the Treatment of Covid-19 - Preliminary Report.|pdf=|usr=009}}
+
−
{{tp|p=32445439|t=2020. Surgery Scheduling in a Crisis.|pdf=|usr=009}}
+
−
{{tp|p=32433465|t=2020. Immunogenicity of a DNA vaccine candidate for COVID-19.|pdf=|usr=009}}
+
−
{{tp|p=32529545|t=2020. Natural Products as Potential Leads Against Coronaviruses: Could They be Encouraging Structural Models Against SARS-CoV-2?|pdf=|usr=009}}
+
−
{{tp|p=32499636|t=2020. COVID-19 vaccines: neutralizing antibodies and the alum advantage.|pdf=|usr=009}}
+
−
{{tp|p=32533109|t=2020. Passive antibody therapy in COVID-19.|pdf=|usr=009}}
+
−
{{tp|p=32393823|t=2020. BCG-induced trained immunity: can it offer protection against COVID-19?|pdf=|usr=009}}
+
−
{{tp|p=32462282|t=2020. Ivermectin, antiviral properties and COVID-19: a possible new mechanism of action.|pdf=|usr=009}}
+
−
{{tp|p=32451597|t=2020. Vitamin D can prevent COVID-19 infection-induced multiple organ damage.|pdf=|usr=009}}
+
−
{{tp|p=32430617|t=2020. A comprehensive review on drug repositioning against coronavirus disease 2019 (COVID19).|pdf=|usr=009}}
+
−
{{tp|p=32350818|t=2020. Chloroquine-induced QTc prolongation in COVID-19 patients.|pdf=|usr=009}}
+
−
{{tp|p=32342609|t=2020. The Use of Non-invasive Vagus Nerve Stimulation to Treat Respiratory Symptoms Associated With COVID-19: A Theoretical Hypothesis and Early Clinical Experience.|pdf=|usr=009}}
+
−
{{tp|p=32383751|t=2020. Beyond Smoking Cessation: Investigating Medicinal Nicotine to Prevent and Treat COVID-19.|pdf=|usr=009}}
+
−
{{tp|p=32528732|t=2020. Universal coronavirus vaccines: the time to start is now.|pdf=|usr=009}}
+
−
{{tp|p=32509338|t=2020. Certainty of success: three critical parameters in coronavirus vaccine development.|pdf=|usr=009}}
+
−
{{tp|p=32521760|t=2020. Diet Supplementation, Probiotics, and Nutraceuticals in SARS-CoV-2 Infection: A Scoping Review.|pdf=|usr=009}}
+
−
{{tp|p=32532069|t=2020. Can Probiotics and Diet Promote Beneficial Immune Modulation and Purine Control in Coronavirus Infection?|pdf=|usr=009}}
+
−
{{tp|p=32519174|t=2020. What can we learn about corticosteroid therapy as a treatment for COVID-19?|pdf=|usr=009}}
+
−
{{tp|p=32528623|t=2020. COVID-19 infection and oxidative stress: an under-explored approach for prevention and treatment?|pdf=|usr=009}}
+
−
{{tp|p=32456404|t=2020. The vaccine journey for COVID-19: a comprehensive systematic review of current clinical trials in humans.|pdf=|usr=009}}
+
−
{{tp|p=32431755|t=2020. The novel immunomodulatory biologic LMWF5A for pharmacological attenuation of the "cytokine storm" in COVID-19 patients: a hypothesis.|pdf=|usr=009}}
+
−
{{tp|p=32451736|t=2020. Repurposing Quaternary Ammonium Compounds as Potential Treatments for COVID-19.|pdf=|usr=009}}
+
−
{{tp|p=32454586|t=2020. Demand for potentially hazardous COVID-19 treatments.|pdf=|usr=009}}
+
−
{{tp|p=32454583|t=2020. ICER releases pricing models for potential COVID-19 treatments.|pdf=|usr=009}}
+
−
{{tp|p=32473310|t=2020. Discovery of the FDA-approved drugs bexarotene, cetilistat, diiodohydroxyquinoline, and abiraterone as potential COVID-19 treatments with a robust two-tier screening system.|pdf=|usr=009}}
+
−
{{tp|p=32445956|t=2020. Review on the potential action mechanisms of Chinese medicines in treating Coronavirus Disease 2019 (COVID-19).|pdf=|usr=009}}
+
−
{{tp|p=32445955|t=2020. Letter to the Editor in response to the article "Could IL-17 represent a new therapeutic target for the treatment and/or management of COVID-19-related respiratory syndrome?"|pdf=|usr=009}}
+
−
{{tp|p=32442720|t=2020. A review of therapeutic agents and Chinese herbal medicines against SARS-COV-2 (COVID-19).|pdf=|usr=009}}
+
−
{{tp|p=32430287|t=2020. Rho kinase inhibitors for SARS-CoV-2 induced acute respiratory distress syndrome: Support from Bartter's and Gitelman's syndrome patients.|pdf=|usr=009}}
+
−
{{tp|p=32430286|t=2020. The possible mechanisms of action of 4-aminoquinolines (chloroquine/hydroxychloroquine) against Sars-Cov-2 infection (COVID-19): A role for iron homeostasis?|pdf=|usr=009}}
+
−
 
+
−
{{tp|p=32405226|t=2020. Anti-malarial drug, artemisinin and its derivatives for the treatment of respiratory diseases.|pdf=|usr=009}}
+
−
{{tp|p=32438037|t=2020. Efficacy and Safety of Integrated Traditional Chinese and Western Medicine for Corona Virus Disease 2019 (COVID-19): a systematic review and meta-analysis.|pdf=|usr=009}}
+
−
{{tp|p=32438034|t=2020. Does lopinavir really inhibit SARS-CoV-2?|pdf=|usr=009}}
+
−
{{tp|p=32407959|t=2020. Compassionate remdesivir treatment of severe Covid-19 pneumonia in intensive care unit (ICU) and Non-ICU patients: Clinical outcome and differences in post-treatment hospitalisation status.|pdf=|usr=009}}
+
−
{{tp|p=32502640|t=2020. Optimising effectiveness of health care and value of clinical trials in the COVID -19 outbreak.|pdf=|usr=009}}
+
−
{{tp|p=32470470|t=2020. Cathepsin L-selective inhibitors: A potentially promising treatment for COVID-19 patients.|pdf=|usr=009}}
+
−
{{tp|p=32442437|t=2020. The proteasome as a druggable target with multiple therapeutic potentialities: Cutting and non-cutting edges.|pdf=|usr=009}}
+
−
{{tp|p=32437972|t=2020. COVID-19: Beyond the virus. The use of Photodynamic Therapy for the Treatment of Infections in the Respiratory Tract.|pdf=|usr=009}}
+
−
{{tp|p=32425361|t=2020. Efficacy and safety of Lianhuaqingwen capsules, a repurposed Chinese herb, in patients with coronavirus disease 2019: A multicenter, prospective, randomized controlled trial.|pdf=|usr=009}}
+
−
{{tp|p=32493609|t=2020. SGLT-2 inhibitors for COVID-19 - A miracle waiting to happen or just another beat around the bush?|pdf=|usr=009}}
+
−
{{tp|p=32519302|t=2020. Mesenchymal stem cell therapy for acute respiratory distress syndrome: from basic to clinics.|pdf=|usr=009}}
+
−
{{tp|p=32415971|t=2020. Use of statins in patients with COVID-19.|pdf=|usr=009}}
+
−
{{tp|p=32415962|t=2020. Reply: Use of statins in patients with COVID-19.|pdf=|usr=009}}
+
−
{{tp|p=32437821|t=2020. Radiation therapy for COVID-19 pneumopathy.|pdf=|usr=009}}
+
−
{{tp|p=32437820|t=2020. Low dose radiation therapy as a potential life saving treatment for COVID-19-induced acute respiratory distress syndrome (ARDS).|pdf=|usr=009}}
+
−
{{tp|p=32413531|t=2020. Lack of supporting data make the risks of a clinical trial of radiation therapy as a treatment for COVID-19 pneumonia unacceptable.|pdf=|usr=009}}
+
−
{{tp|p=32522574|t=2020. Coping with hypoxemia: Could erythropoietin (EPO) be an adjuvant treatment of COVID-19?|pdf=|usr=009}}
+
−
{{tp|p=32514354|t=2020. High-dose, short-term corticosteroids for ARDS caused by COVID-19: a case series.|pdf=|usr=009}}
+
−
{{tp|p=32394513|t=2020. Chloroquine and hydroxychloroquine for COVID-19: A word of caution.|pdf=|usr=009}}
+
−
{{tp|p=32426002|t=2020. Opciones Terapeuticas En El Manejo De Covid-19 Grave: Una Perspectiva De Reumatologia.|pdf=|usr=009}}
+
−
{{tp|p=32426001|t=2020. Colchicina: una herramienta terapeutica potencial frente a COVID-19. Experiencia en 5 pacientes.|pdf=|usr=009}}
+
−
{{tp|p=32395001|t=2020. Evidencia viva como respuesta a las controversias en el uso de antimalaricos en COVID-19.|pdf=|usr=009}}
+
−
{{tp|p=32414660|t=2020. Exercising in times of COVID-19: what do experts recommend doing within four walls?|pdf=|usr=009}}
+
−
{{tp|p=32491104|t=2020. Clinical characteristics and therapeutic procedure for a critical case of novel coronavirus pneumonia treated with glucocorticoids and non-invasive ventilator treatment.|pdf=|usr=009}}
+
−
{{tp|p=32501367|t=2020. Chloroquine dosage regimens in patients with COVID-19: Safety risks and optimization using simulations.|pdf=|usr=009}}
+
−
{{tp|p=32418114|t=2020. Low dose of hydroxychloroquine reduces fatality of critically ill patients with COVID-19.|pdf=|usr=009}}
+
−
{{tp|p=32518317|t=2020. Sofosbuvir as a potential alternative to treat the SARS-CoV-2 epidemic.|pdf=|usr=009}}
+
−
{{tp|p=32413619|t=2020. beta-Glucan extracts from the same edible shiitake mushroom Lentinus edodes produce differential in-vitro immunomodulatory and pulmonary cytoprotective effects - Implications for coronavirus disease (COVID-19) immunotherapies.|pdf=|usr=009}}
+
−
{{tp|p=32513867|t=2020. Antibody signature induced by SARS-CoV-2 spike protein immunogens in rabbits.|pdf=|usr=009}}
+
−
{{tp|p=32434945|t=2020. DNA vaccine protection against SARS-CoV-2 in rhesus macaques.|pdf=|usr=009}}
+
−
{{tp|p=32404477|t=2020. A noncompeting pair of human neutralizing antibodies block COVID-19 virus binding to its receptor ACE2.|pdf=|usr=009}}
+
−
{{tp|p=32385228|t=2020. Therapeutic efficacy of Pudilan Xiaoyan Oral Liquid (PDL) for COVID-19 in vitro and in vivo.|pdf=|usr=009}}
+
−
{{tp|p=32467561|t=2020. Immune response in COVID-19: addressing a pharmacological challenge by targeting pathways triggered by SARS-CoV-2.|pdf=|usr=009}}
+
−
{{tp|p=32460839|t=2020. Intravenous infusion of human umbilical cord Wharton's jelly-derived mesenchymal stem cells as a potential treatment for patients with COVID-19 pneumonia.|pdf=|usr=009}}
+
−
{{tp|p=32526079|t=2020. Current status of mesenchymal stem cell therapy for immune/inflammatory lung disorders: Gleaning insights for possible use in COVID-19.|pdf=|usr=009}}
+
−
{{tp|p=32388805|t=2020. Low-dose radiation therapy for COVID-19 pneumopathy: what is the evidence?|pdf=|usr=009}}
+
−
{{tp|p=32394099|t=2020. Low-dose radiotherapy for SARS-CoV-2 pneumonia.|pdf=|usr=009}}
+
−
{{tp|p=32412544|t=2020. In silico fight against novel coronavirus by finding chromone derivatives as inhibitor of coronavirus main proteases enzyme.|pdf=|usr=009}}
+
−
{{tp|p=32528195|t=2020. Broad beans (Vicia faba) and the potential to protect from COVID-19 coronavirus infection.|pdf=|usr=009}}
+
−
{{tp|p=32528194|t=2020. Perspectives on repositioning chloroquine and hydroxychloroquine for the treatment of Covid-19.|pdf=|usr=009}}
+
−
{{tp|p=32436460|t=2020. TNFalpha inhibitor may be effective for severe COVID-19: learning from toxic epidermal necrolysis.|pdf=|usr=009}}
+
−
{{tp|p=32436445|t=2020. Potential specific therapies in COVID-19.|pdf=|usr=009}}
+
−
{{tp|p=32483428|t=2020. Optimizing use of theranostic nanoparticles as a life-saving strategy for treating COVID-19 patients.|pdf=|usr=009}}
+
−
{{tp|p=32473812|t=2020. Chloroquine and hydroxychloroquine in the management of COVID-19: Much kerfuffle but little evidence.|pdf=|usr=009}}
+
−
{{tp|p=32418732|t=2020. Chloroquine and hydroxychloroquine during pregnancy: What do we know?|pdf=|usr=009}}
+
−
{{tp|p=32457932|t=2020. Chloroquine, hydroxychloroquine and COVID-19.|pdf=|usr=009}}
+
−
{{tp|p=32487513|t=2020. Convalescent (immune) plasma treatment in a myelodysplastic COVID-19 patient with disseminated tuberculosis.|pdf=|usr=009}}
+
−
{{tp|p=32532691|t=2020. Position paper on the preparation of immune plasma to be used in the treatment of patients with COVID-19.|pdf=|usr=009}}
+
−
{{tp|p=32467007|t=2020. Successful treatment of a centenarian with coronavirus disease 2019 (COVID-19) using convalescent plasma.|pdf=|usr=009}}
+
−
{{tp|p=32425645|t=2020. Use of convalescent plasma in COVID-19 patients in China.|pdf=|usr=009}}
+
−
{{tp|p=32406985|t=2020. Interleukin-6 receptor antagonist therapy to treat SARS-CoV-2 driven inflammatory syndrome in a kidney transplant recipient.|pdf=|usr=009}}
+
−
{{tp|p=32473994|t=2020. Crushing lopinavir-ritonavir tablets may decrease the efficacy of therapy in COVID-19 patients.|pdf=|usr=009}}
+
−
{{tp|p=32485391|t=2020. Hydroxychloroquine-azithromycin for COVID-19 - Warranted or dangerous?|pdf=|usr=009}}
+
−
{{tp|p=32360423|t=2020. Malaria prophylaxis approach during COVID-19 pandemic.|pdf=|usr=009}}
+
−
{{tp|p=32471655|t=2020. Overwhelming COVID-19 Clinical Trials: Call for Prospective Meta-Analyses.|pdf=|usr=009}}
+
−
{{tp|p=32454984|t=2020. Battling COVID-19: using old weapons for a new enemy.|pdf=|usr=009}}
+
−
{{tp|p=32376108|t=2020. Archetype analysis of older adult immunization decision-making and implementation in 34 countries.|pdf=|usr=009}}
+
−
{{tp|p=32387011|t=2020. Tortoises, hares, and vaccines: A cautionary note for SARS-CoV-2 vaccine development.|pdf=|usr=009}}
+
−
{{tp|p=32418794|t=2020. A Veterinary Vaccine Development Process Map to assist in the development of new vaccines.|pdf=|usr=009}}
+
−
{{tp|p=32526960|t=2020. Immunoinformatics and Structural Analysis for Identification of Immunodominant Epitopes in SARS-CoV-2 as Potential Vaccine Targets.|pdf=|usr=009}}
+
−
{{tp|p=32531955|t=2020. Prospects of Replication-Deficient Adenovirus Based Vaccine Development against SARS-CoV-2.|pdf=|usr=009}}
+
−
{{tp|p=32236815|t=2020. Inefficiency of Sera from Mice Treated with Pseudotyped SARS-CoV to Neutralize 2019-nCoV Infection.|pdf=|usr=009}}
+
−
{{tp|p=32524253|t=2020. mRNA Vaccines: Possible Tools to Combat SARS-CoV-2.|pdf=|usr=009}}
+
−
{{tp|p=32530808|t=2020. Recovery of severely ill COVID-19 patients by intravenous immunoglobulin (IVIG) treatment: A case series.|pdf=|usr=009}}
+
−
{{tp|p=32531236|t=2020. Potential drugs for the treatment of the novel coronavirus pneumonia (COVID-19) in China.|pdf=|usr=009}}
+
−
{{tp|p=32532094|t=2020. The Anticoagulant Nafamostat Potently Inhibits SARS-CoV-2 S Protein-Mediated Fusion in a Cell Fusion Assay System and Viral Infection In Vitro in a Cell-Type-Dependent Manner.|pdf=|usr=009}}
+
−
{{tp|p=32532085|t=2020. Broad-Spectrum Host-Based Antivirals Targeting the Interferon and Lipogenesis Pathways as Potential Treatment Options for the Pandemic Coronavirus Disease 2019 (COVID-19).|pdf=|usr=009}}
+
−
{{tp|p=32426090|t=2020. COVID-19, asthma, and biologic therapies: What we need to know.|pdf=|usr=009}}
+
−
{{tp|p=32417996|t=2020. BCG versus COVID-19: impact on urology.|pdf=|usr=009}}
+
−
{{tp|p=32514854|t=2020. Biologikatherapie nach COVID-19-Infektion : Keine Reaktivierung einer COVID-19-Infektion bei positivem Antikorperstatus SARS-CoV-2 unter Biologikatherapie.|pdf=|usr=009}}
+
−
 
+
−
PMC searches were done at moremed.org
+
−
 
+
−
 
+
−
 
+
−
 
+
−
{{tp|p=32581256|t=2020. Recombinant human ACE2: potential therapeutics of SARS-CoV-2 infection and its complication.|pdf=|usr=010}}
+
−
{{tp|p=32555446|t=2020. Overview of therapeutic drug research for COVID-19 in China.|pdf=|usr=010}}
+
−
{{tp|p=32544884|t=2020. De novo design of protein peptides to block association of the SARS-CoV-2 spike protein with human ACE2.|pdf=|usr=010}}
+
−
{{tp|p=32574894|t=2020. Repurposing 0.5% povidone iodine solution in otorhinolaryngology practice in Covid 19 pandemic.|pdf=|usr=010}}
+
−
{{tp|p=32583087|t=2020. IL-1R blockade is not effective in patients with hematological malignancies and severe SARS-CoV-2 infection.|pdf=|usr=010}}
+
−
{{tp|p=32551892|t=2020. Update Alert: Should Clinicians Use Chloroquine or Hydroxychloroquine Alone or in Combination With Azithromycin for the Prophylaxis or Treatment of COVID-19? Living Practice Points From the American College of Physicians.|pdf=|usr=010}}
+
−
{{tp|p=32543882|t=2020. Promoting Better Clinical Trials and Drug Information as Public Health Interventions for the COVID-19 Emergency in Italy.|pdf=|usr=010}}
+
−
{{tp|p=32571831|t=2020. IMPACT OF GLUCOCORTICOID TREATMENT IN SARS-COV-2 INFECTION MORTALITY: A RETROSPECTIVE CONTROLLED COHORT STUDY.|pdf=|usr=010}}
+
−
{{tp|p=32575554|t=2020. Targeting the Heme-Heme Oxygenase System to Prevent Severe Complications Following COVID-19 Infections.|pdf=|usr=010}}
+
−
{{tp|p=32562705|t=2020. A library of nucleotide analogues terminate RNA synthesis catalyzed by polymerases of coronaviruses that cause SARS and COVID-19.|pdf=|usr=010}}
+
−
{{tp|p=32557214|t=2020. Potential Role of Anti-interleukin (IL)-6 Drugs in the Treatment of COVID-19: Rationale, Clinical Evidence and Risks.|pdf=|usr=010}}
+
−
{{tp|p=32586336|t=2020. A prospect on the use of antiviral drugs to control local outbreaks of COVID-19.|pdf=|usr=010}}
+
−
{{tp|p=32554525|t=2020. Clinical efficacy of hydroxychloroquine in patients with covid-19 pneumonia who require oxygen: observational comparative study using routine care data.|pdf=|usr=010}}
+
−
{{tp|p=32572174|t=2020. Repurposing anticancer drugs for COVID-19-induced inflammation, immune dysfunction, and coagulopathy.|pdf=|usr=010}}
+
−
{{tp|p=32546835|t=2020. Immune checkpoint blockade: releasing the breaks or a protective barrier to COVID-19 severe acute respiratory syndrome?|pdf=|usr=010}}
+
−
{{tp|p=32557011|t=2020. A Double-Edged Sword-Cardiovascular Concerns of Potential Anti-COVID-19 Drugs.|pdf=|usr=010}}
+
−
{{tp|p=32492407|t=2020. Pandemic Preparedness: Developing Vaccines and Therapeutic Antibodies For COVID-19.|pdf=|usr=010}}
+
−
{{tp|p=32546764|t=2020. Immunity-and-matrix-regulatory cells derived from human embryonic stem cells safely and effectively treat mouse lung injury and fibrosis.|pdf=|usr=010}}
+
−
{{tp|p=32541865|t=2020. Boceprevir, GC-376, and calpain inhibitors II, XII inhibit SARS-CoV-2 viral replication by targeting the viral main protease.|pdf=|usr=010}}
+
−
{{tp|p=32588163|t=2020. Auxiliary role of mesenchymal stem cells as regenerative medicine soldiers to attenuate inflammatory processes of severe acute respiratory infections caused by COVID-19.|pdf=|usr=010}}
+
−
{{tp|p=32585295|t=2020. Inhibition of cytokine signaling by ruxolitinib and implications for COVID-19 treatment.|pdf=|usr=010}}
+
−
{{tp|p=32564213|t=2020. The rationale for the use of colchicine in COVID-19: comments on the letter by Cumhur Cure M et al.|pdf=|usr=010}}
+
−
{{tp|p=32564212|t=2020. Comment on "Colchicine may not be effective in COVID-19 infection; it may even be harmful?"|pdf=|usr=010}}
+
−
{{tp|p=32556936|t=2020. Colchicine as a possible therapeutic option in COVID-19 infection.|pdf=|usr=010}}
+
−
{{tp|p=32548723|t=2020. Impact of anti-rheumatic drugs and steroids on clinical course and prognosis of COVID-19.|pdf=|usr=010}}
+
−
{{tp|p=32542396|t=2020. Decoy ACE2-expressing extracellular vesicles that competitively bind SARS-CoV-2 as a possible COVID-19 therapy.|pdf=|usr=010}}
+
−
{{tp|p=32593060|t=2020. Helping doctors hasten COVID-19 treatment: Towards a rescue framework for the transfusion of best convalescent plasma to the most critical patients based on biological requirements via ml and novel MCDM methods.|pdf=|usr=010}}
+
−
{{tp|p=32558354|t=2020. Timing of antiviral treatment initiation is critical to reduce SARS-CoV-2 viral load.|pdf=|usr=010}}
+
−
{{tp|p=32552848|t=2020. Compassionate use of others' immunity - understanding gut microbiome in Covid-19.|pdf=|usr=010}}
+
−
{{tp|p=32552832|t=2020. First do no harm-beware the risk of therapeutic plasma exchange in severe COVID-19.|pdf=|usr=010}}
+
−
{{tp|p=32572376|t=2020. Literature-based review of the drugs used for the treatment of COVID-19.|pdf=|usr=010}}
+
−
{{tp|p=32578027|t=2020. A Rapid Advice Guideline for the Prevention of Novel Coronavirus Through Nutritional Intervention.|pdf=|usr=010}}
+
−
{{tp|p=32562159|t=2020. The clinical value of two combination regimens in the Management of Patients Suffering from Covid-19 pneumonia: a single centered, retrospective, observational study.|pdf=|usr=010}}
+
−
{{tp|p=32542964|t=2020. Treatment of Covid19 - Repurposing drugs commonly used in dermatology.|pdf=|usr=010}}
+
−
{{tp|p=32542893|t=2020. Acute generalized exanthematous pustulosis induced by empiric hydroxychloroquine for presumed COVID-19.|pdf=|usr=010}}
+
−
{{tp|p=32537890|t=2020. Observation and consideration on using of JAKi in clinical trials in times of COVID-19.|pdf=|usr=010}}
+
−
{{tp|p=32592841|t=2020. A proposed mechanism for the possible therapeutic potential of Metformin in COVID-19.|pdf=|usr=010}}
+
−
{{tp|p=32581194|t=2020. Targeting lymphocyte Kv1.3-channels to suppress cytokine storm in severe COVID-19: Can it be a novel therapeutic strategy?|pdf=|usr=010}}
+
−
{{tp|p=32554953|t=2020. Can mesenchymal stem cell therapy be the interim management of COVID-19?|pdf=|usr=010}}
+
−
{{tp|p=32592866|t=2020. Emerging vaccine delivery systems for COVID-19: Functionalised silica nanoparticles offer a potentially safe and effective alternative delivery system for DNA/RNA vaccines and may be useful in the hunt for a COVID-19 vaccine.|pdf=|usr=010}}
+
−
{{tp|p=32574699|t=2020. Discovering small-molecule therapeutics against SARS-CoV-2.|pdf=|usr=010}}
+
−
{{tp|p=32574697|t=2020. Current and future therapeutical approaches for COVID-19.|pdf=|usr=010}}
+
−
{{tp|p=32569833|t=2020. Exportin 1 inhibition as antiviral therapy.|pdf=|usr=010}}
+
−
{{tp|p=32546018|t=2020. The broad-spectrum antiviral recommendations for drug discovery against COVID-19.|pdf=|usr=010}}
+
−
{{tp|p=32578156|t=2020. Lopinavir-Ritonavir in the Treatment of COVID-19: A Dynamic Systematic Benefit-Risk Assessment.|pdf=|usr=010}}
+
−
{{tp|p=32592145|t=2020. Identification of a Potential Peptide Inhibitor of SARS-CoV-2 Targeting its Entry into the Host Cells.|pdf=|usr=010}}
+
−
{{tp|p=32574958|t=2020. Targeting innate immunity by blocking CD14: Novel approach to control inflammation and organ dysfunction in COVID-19 illness.|pdf=|usr=010}}
+
−
{{tp|p=32573433|t=2020. Antibodies to SARS-CoV-2 and their potential for therapeutic passive immunization.|pdf=|usr=010}}
+
−
{{tp|p=32569446|t=2020. Can artificial intelligence identify effective COVID-19 therapies?|pdf=|usr=010}}
+
−
{{tp|p=32579067|t=2020. In Vivo Expressed Biologics for Infectious Disease Prophylaxis: Rapid Delivery of DNA-Based Antiviral Antibodies.|pdf=|usr=010}}
+
−
{{tp|p=32562594|t=2020. Pregnant Women in Trials of COVID-19: A Critical Time to Consider Ethical Frameworks of Inclusion in Clinical Trials.|pdf=|usr=010}}
+
−
{{tp|p=32548679|t=2020. Calling for an exponential escalation scheme in vaccine development for COVID-19.|pdf=|usr=010}}
+
−
{{tp|p=32591957|t=2020. Once we have it, will we use it? A European survey on willingness to be vaccinated against COVID-19.|pdf=|usr=010}}
+
−
{{tp|p=32561291|t=2020. Endoplasmic reticulum as a potential therapeutic target for covid-19 infection management?|pdf=|usr=010}}
+
−
{{tp|p=32554535|t=2020. Potential role of memantine in the prevention and treatment of COVID-19: its antagonism of nicotinic acetylcholine receptors (nAChR) and beyond.|pdf=|usr=010}}
+
−
{{tp|p=32589055|t=2020. Vesicular drug-delivery systems as theranostics in COVID-19.|pdf=|usr=010}}
+
−
{{tp|p=32564623|t=2020. Tackling SARS-CoV-2: proposed targets and repurposed drugs.|pdf=|usr=010}}
+
−
{{tp|p=32578073|t=2020. Elderly at time of COronaVIrus disease 2019 (COVID-19): possible role of immunosenescence and malnutrition.|pdf=|usr=010}}
+
−
{{tp|p=32577840|t=2020. Introduction: microbes, networks, knowledge-disease ecology and emerging infectious diseases in time of COVID-19.|pdf=|usr=010}}
+
−
{{tp|p=32544304|t=2020. Antiretroviral HIV drugs in COVID-19 research: promises and risks. An opinion piece.|pdf=|usr=010}}
+
−
{{tp|p=32591003|t=2020. Application of CRISPR/Cas9 to human-induced pluripotent stem cells: from gene editing to drug discovery.|pdf=|usr=010}}
+
−
{{tp|p=32546029|t=2020. Case report: use of lenzilumab and tocilizumab for the treatment of coronavirus disease 2019.|pdf=|usr=010}}
+
−
{{tp|p=32565362|t=2020. Comparative analysis of SARS-CoV-2 receptor ACE2 expression in multiple solid tumors and matched non-diseased tissues.|pdf=|usr=010}}
+
−
{{tp|p=32588335|t=2020. COVID-19, equipoise and observational studies: a reminder of forgotten issues.|pdf=|usr=010}}
+
−
{{tp|p=32557206|t=2020. Rapid radiological improvement of COVID-19 pneumonia after treatment with tocilizumab.|pdf=|usr=010}}
+
−
{{tp|p=32582401|t=2020. Therapeutic potential of mesenchymal stem cells and their exosomes in severe novel coronavirus disease 2019 (COVID-19) cases.|pdf=|usr=010}}
+
−
{{tp|p=32582400|t=2020. Steps towards COVID-19 suppression.|pdf=|usr=010}}
+
−
{{tp|p=32585611|t=2020. Potential adjuvants for the development of a SARS-CoV-2 vaccine based on experimental results from similar coronaviruses.|pdf=|usr=010}}
+
−
{{tp|p=32565195|t=2020. Chloroquine cardiac effects and toxicity.A short update.|pdf=|usr=010}}
+
−
{{tp|p=32585284|t=2020. Therapeutic Plasma Exchange in Adults with Severe COVID-19 Infection.|pdf=|usr=010}}
+
−
{{tp|p=32579907|t=2020. Paromomycin: a potential dual targeted drug effectively inhibits both Spike (S1) and Main Protease of COVID-19.|pdf=|usr=010}}
+
−
{{tp|p=32585194|t=2020. Convalescent plasma therapy in the treatment of COVID-19: Some considerations: Correspondence.|pdf=|usr=010}}
+
−
{{tp|p=32592113|t=2020. Potential role of incretins in diabetes and COVID-19 infection: a hypothesis worth exploring.|pdf=|usr=010}}
+
−
{{tp|p=32564289|t=2020. The SARS-CoV-2 receptor, ACE-2, is expressed on many different cell types: implications for ACE-inhibitor- and angiotensin II receptor blocker-based cardiovascular therapies: comment.|pdf=|usr=010}}
+
−
{{tp|p=32572516|t=2020. Remdesivir bei Patienten mit COVID-19.|pdf=|usr=010}}
+
−
{{tp|p=32588377|t=2020. Corticosteroids in diabetes patients infected with COVID-19.|pdf=|usr=010}}
+
−
{{tp|p=32583443|t=2020. Letter: intestinal inflammation, COVID-19 and gastrointestinal ACE2-exploring RAS inhibitors-authors' reply.|pdf=|usr=010}}
+
−
{{tp|p=32578215|t=2020. Could Anti-Tubercular Vaccination Protect Against Covid-19 Infection?|pdf=|usr=010}}
+
−
{{tp|p=32552021|t=2020. From "Infodemics" to Health Promotion: A Novel Framework for the Role of Social Media in Public Health.|pdf=|usr=010}}
+
−
{{tp|p=32579022|t=2020. Lung Mechanics in COVID-19 Resemble RDS not ARDS: Could Surfactant be a Treatment?|pdf=|usr=010}}
+
−
{{tp|p=32579020|t=2020. Treatment of COVID-19 by Inhaled NO to Reduce Shunt?|pdf=|usr=010}}
+
−
{{tp|p=32551560|t=2020. Discovery of Aptamers Targeting Receptor-Binding Domain of the SARS-CoV-2 Spike Glycoprotein.|pdf=|usr=010}}
+
−
{{tp|p=32585180|t=2020. Use of inhaled corticosteroids in asthma and COVID-19 : Keep calm and carry on.|pdf=|usr=010}}
+
−
{{tp|p=32539520|t=2020. In COVID-19, adding lopinavir-ritonavir to usual care did not shorten time to clinical improvement.|pdf=|usr=010}}
+
−
{{tp|p=32561608|t=2020. Role of antimalarials in COVID-19: observational data from a cohort of rheumatic patients.|pdf=|usr=010}}
+
−
{{tp|p=32574109|t=2020. Structural Basis of the SARS-CoV-2/SARS-CoV Receptor Binding and Small-Molecule Blockers as Potential Therapeutics.|pdf=|usr=010}}
+
−
{{tp|p=32589165|t=2020. SARS-CoV-2 and HIV protease inhibitors: why lopinavir/ritonavir will not work for COVID-19 infection.|pdf=|usr=010}}
+
−
{{tp|p=32551883|t=2020. COVID-19 and the Drug Repurposing Tsunami.|pdf=|usr=010}}
+
−
{{tp|p=32573724|t=2020. Improved Clinical Symptoms and Mortality on Severe/Critical COVID-19 Patients Utilizing Convalescent Plasma Transfusion.|pdf=|usr=010}}
+
−
{{tp|p=32559767|t=2020. Use of Convalescent Plasma in Hospitalized Patients with Covid-19 - Case Series.|pdf=|usr=010}}
+
−
{{tp|p=32576548|t=2020. Covid-19: Demand for dexamethasone surges as RECOVERY trial publishes preprint.|pdf=|usr=010}}
+
−
{{tp|p=32546467|t=2020. Covid-19: Low dose steroid cuts death in ventilated patients by one third, trial finds.|pdf=|usr=010}}
+
−
{{tp|p=32540958|t=2020. Hydroxychloroquine for covid-19: the end of the line?|pdf=|usr=010}}
+
−
{{tp|p=32556143|t=2020. Compassionate use of hydroxychloroquine in clinical practice for patients with mild to severe Covid-19 in a French university hospital.|pdf=|usr=010}}
+
−
{{tp|p=32548616|t=2020. Corticosteroids in patients with COVID-19: what about the control group?|pdf=|usr=010}}
+
−
{{tp|p=32588427|t=2020. QT interval prolongation under hydroxychloroquine/ azithromycin association for inpatients with SARS-CoV-2 lower respiratory tract infection.|pdf=|usr=010}}
+
−
{{tp|p=32589775|t=2020. Safety, Tolerability, and Pharmacokinetics of Remdesivir, an Antiviral for Treatment of COVID-19, in Healthy Subjects.|pdf=|usr=010}}
+
−
{{tp|p=32552642|t=2020. Facts and myths: Efficacies of repurposing chloroquine and hydroxychloroquine for the treatment of COVID-19.|pdf=|usr=010}}
+
−
{{tp|p=32584431|t=2020. Colchicin Treatment of Covid-19 Presenting With Cutaneous Rash and Myopericarditis.|pdf=|usr=010}}
+
−
{{tp|p=32562762|t=2020. SGLT2 inhibition during the COVID-19 epidemic: Friend or foe?|pdf=|usr=010}}
+
−
{{tp|p=32592507|t=2020. Hydroxychloroquine, COVID-19 and diabetes. Why it is a different story.|pdf=|usr=010}}
+
−
{{tp|p=32588937|t=2020. Adjustments in analyses of vitamin D status, allowing for vitamin D determinants, for Covid-19 risks.|pdf=|usr=010}}
+
−
{{tp|p=32559771|t=2020. The Battle against COVID 19 Pandemic: What we Need to Know Before we "Test Fire" Ivermectin.|pdf=|usr=010}}
+
−
{{tp|p=32588530|t=2020. RNA to the rescue: RNA is one of the most promising targets for drug development given its wide variety of uses.|pdf=|usr=010}}
+
−
{{tp|p=32567239|t=2020. Advantages of Using Lotteries to Select Participants for High-Demand Covid-19 Treatment Trials.|pdf=|usr=010}}
+
−
{{tp|p=32543297|t=2020. Why do SARS-COV vaccines not exist? The pharma scientific intelligence and business model must be revisited!|pdf=|usr=010}}
+
−
{{tp|p=32574081|t=2020. Can nanotechnology help in the fight against COVID-19?|pdf=|usr=010}}
+
−
{{tp|p=32552044|t=2020. Repurposing minocycline for COVID-19 management: mechanisms, opportunities, and challenges.|pdf=|usr=010}}
+
−
{{tp|p=32576053|t=2020. Opioids/cannabinoids as a potential therapeutic approach in COVID-19 patients.|pdf=|usr=010}}
+
−
{{tp|p=32553760|t=2020. TNFalpha-antagonist use and mucosal inflammation are associated with increased intestinal expression of SARS-CoV-2 host protease TMPRSS2 in patients with inflammatory bowel disease.|pdf=|usr=010}}
+
−
{{tp|p=32553757|t=2020. Aminosalicylates and COVID-19: Facts or Coincidences?|pdf=|usr=010}}
+
−
{{tp|p=32554621|t=2020. Infliximab for severe ulcerative colitis and subsequent SARS-CoV-2 pneumonia: a stone for two birds.|pdf=|usr=010}}
+
−
 
+
−
{{tp|p=32557648|t=2020. Vaccine development and therapeutic design for 2019-nCoV/SARS-CoV-2: Challenges and chances.|pdf=|usr=010}}
+
−
{{tp|p=32557541|t=2020. A Comprehensive Review on Tocilizumab in COVID-19 Acute Respiratory Distress Syndrome.|pdf=|usr=010}}
+
−
{{tp|p=32561274|t=2020. In silico prediction of potential inhibitors for the Main protease of SARS-CoV-2 using molecular docking and dynamics simulation based drug-repurposing.|pdf=|usr=010}}
+
−
{{tp|p=32567262|t=2020. A Case of Breakthrough COVID-19 during Hydroxychloroquine Maintenance.|pdf=|usr=010}}
+
−
{{tp|p=32537956|t=2020. Uncertainty about the Efficacy of Remdesivir on COVID-19.|pdf=|usr=010}}
+
−
{{tp|p=32539378|t=2020. Inhibitors of SARS-CoV-2 Entry: Current and Future Opportunities.|pdf=|usr=010}}
+
−
{{tp|p=32562701|t=2020. Apelin-potential therapy for COVID-19?|pdf=|usr=010}}
+
−
{{tp|p=32588188|t=2020. Comment on "Smooth or Risky Revisit of an Old Malaria Drug for COVID-19?"|pdf=|usr=010}}
+
−
{{tp|p=32565096|t=2020. Anticipating SARS-CoV-2 Vaccine Testing, Licensure, and Recommendations for Use.|pdf=|usr=010}}
+
−
{{tp|p=32543196|t=2020. Repositioning of 8565 Existing Drugs for COVID-19.|pdf=|usr=010}}
+
−
{{tp|p=32586380|t=2020. Advanced bioinformatics rapidly identifies existing therapeutics for patients with coronavirus disease-2019 (COVID-19).|pdf=|usr=010}}
+
−
{{tp|p=32591466|t=2020. SARS-CoV-2 vaccines: 'Warp Speed' needs mind melds not warped minds.|pdf=|usr=010}}
+
−
{{tp|p=32589146|t=2020. Statistical Issues and Lessons Learned from COVID-19 Clinical Trials with Lopinavir-Ritonavir and Remdesivir.|pdf=|usr=010}}
+
−
{{tp|p=32536150|t=2020. Lopinavir-ritonavir versus hydroxychloroquine for viral clearance and clinical improvement in patients with mild to moderate coronavirus disease 2019.|pdf=|usr=010}}
+
−
{{tp|p=32553190|t=2020. Appropriate selection of convalescent plasma donors for COVID-19.|pdf=|usr=010}}
+
−
{{tp|p=32555367|t=2020. Regional BCG vaccination policy in former East- and West Germany may impact on both severity of SARS-CoV-2 and incidence of childhood leukemia.|pdf=|usr=010}}
+
−
{{tp|p=32555296|t=2020. Ruxolitinib for the treatment of SARS-CoV-2 induced acute respiratory distress syndrome (ARDS).|pdf=|usr=010}}
+
−
{{tp|p=32553928|t=2020. Potential inhibitors of the interaction between ACE2 and SARS-CoV-2 (RBD), to develop a drug.|pdf=|usr=010}}
+
−
{{tp|p=32561657|t=2020. Could an Unrelated Live Attenuated Vaccine Serve as a Preventive Measure To Dampen Septic Inflammation Associated with COVID-19 Infection?|pdf=|usr=010}}
+
−
{{tp|p=32590324|t=2020. Targeting adenosinergic pathway and adenosine A2A receptor signaling for the treatment of COVID-19: A hypothesis.|pdf=|usr=010}}
+
−
{{tp|p=32575019|t=2020. Pirfenidone: A novel hypothetical treatment for COVID-19.|pdf=|usr=010}}
+
−
{{tp|p=32558640|t=2020. Cibler la protease majeure du SARS-CoV-2 pour fabriquer un medicament efficace contre ce coronavirus.|pdf=|usr=010}}
+
−
{{tp|p=32590819|t=2020. Critically ill patients with COVID-19 with ECMO and artificial liver plasma exchange: A retrospective study.|pdf=|usr=010}}
+
−
{{tp|p=32574789|t=2020. Predictive factors of mortality in patients treated with tocilizumab for acute respiratory distress syndrome related to coronavirus disease 2019 (COVID-19).|pdf=|usr=010}}
+
−
{{tp|p=32570850|t=2020. Microbiota Modulating Nutritional Approaches to Countering the Effects of Viral Respiratory Infections Including SARS-CoV-2 through Promoting Metabolic and Immune Fitness with Probiotics and Plant Bioactives.|pdf=|usr=010}}
+
−
{{tp|p=32546125|t=2020. Erythropoietin as candidate for supportive treatment of severe COVID-19.|pdf=|usr=010}}
+
−
{{tp|p=32560203|t=2020. Quinoxaline Derivatives as Antiviral Agents: A Systematic Review.|pdf=|usr=010}}
+
−
{{tp|p=32551679|t=2020. Cellular Nanosponges Inhibit SARS-CoV-2 Infectivity.|pdf=|usr=010}}
+
−
{{tp|p=32557405|t=2020. Recognition of Natural Products as Potential Inhibitors of COVID-19 Main Protease (Mpro): In-Silico Evidences.|pdf=|usr=010}}
+
−
{{tp|p=32576980|t=2020. GM-CSF-based treatments in COVID-19: reconciling opposing therapeutic approaches.|pdf=|usr=010}}
+
−
{{tp|p=32572246|t=2020. Preclinical data from SARS-CoV-2 mRNA vaccine.|pdf=|usr=010}}
+
−
{{tp|p=32555401|t=2020. Optimizing safety surveillance for COVID-19 vaccines.|pdf=|usr=010}}
+
−
{{tp|p=32587103|t=2020. Extending rituximab dosing intervals in patients with MS during the COVID-19 pandemic and beyond?|pdf=|usr=010}}
+
−
{{tp|p=32590117|t=2020. Nitric oxide dosed in short bursts at high concentrations may protect against Covid 19.|pdf=|usr=010}}
+
−
{{tp|p=32405159|t=2020. May statins and PCSK9 inhibitors be protective from COVID-19 in familial hypercholesterolemia subjects?|pdf=|usr=010}}
+
−
{{tp|p=32564413|t=2020. Is 0.5% Hydrogen Peroxide Effective against SARS-CoV-2?|pdf=|usr=010}}
+
−
{{tp|p=32587806|t=2020. A potential role for Galectin-3 inhibitors in the treatment of COVID-19.|pdf=|usr=010}}
+
−
{{tp|p=32590099|t=2020. The database-based strategy may overstate the potential effects of traditional Chinese medicine against COVID-19.|pdf=|usr=010}}
+
−
{{tp|p=32569819|t=2020. Network pharmacological approach for elucidating the mechanisms of traditional Chinese medicine in treating COVID-19 patients.|pdf=|usr=010}}
+
−
{{tp|p=32565309|t=2020. Effect of combination antiviral therapy on hematological profiles in 151 adults hospitalized with severe coronavirus disease 2019.|pdf=|usr=010}}
+
−
{{tp|p=32592716|t=2020. Glycyrrhizin: An alternative drug for the treatment of COVID-19 infection and the associated respiratory syndrome?|pdf=|usr=010}}
+
−
{{tp|p=32562826|t=2020. Therapeutic potential of resveratrol against emerging respiratory viral infections.|pdf=|usr=010}}
+
−
{{tp|p=32542785|t=2020. Baricitinib: A review of pharmacology, safety and emerging clinical experience in COVID-19.|pdf=|usr=010}}
+
−
{{tp|p=32592911|t=2020. Does PDT have potential in the treatment of COVID 19 patients?|pdf=|usr=010}}
+
−
{{tp|p=32585401|t=2020. Optical theranostics and treatment dosimetry for COVID-19 lung complications: towards increasing the survival rate of vulnerable populations.|pdf=|usr=010}}
+
−
{{tp|p=32585400|t=2020. Ultraviolet-based biophotonic technologies for control and prevention of COVID-19, SARS and related disorders.|pdf=|usr=010}}
+
−
{{tp|p=32561979|t=2020. Synergistic antiviral effects against SARS-CoV-2 by plant-based molecules.|pdf=|usr=010}}
+
−
{{tp|p=32575476|t=2020. Geranium and Lemon Essential Oils and Their Active Compounds Downregulate Angiotensin-Converting Enzyme 2 (ACE2), a SARS-CoV-2 Spike Receptor-Binding Domain, in Epithelial Cells.|pdf=|usr=010}}
+
−
{{tp|p=32569450|t=2020. Ritonavir/Lopinavir and Its Potential Interactions With Psychiatric Medications: A COVID-19 Perspective.|pdf=|usr=010}}
+
−
{{tp|p=32570995|t=2020. Short-Term Dexamethasone in Sars-CoV-2 Patients.|pdf=|usr=010}}
+
−
{{tp|p=32552811|t=2020. E-cigarette-induced pulmonary inflammation and dysregulated repair are mediated by nAChR alpha7 receptor: role of nAChR alpha7 in SARS-CoV-2 Covid-19 ACE2 receptor regulation.|pdf=|usr=010}}
+
−
{{tp|p=32558034|t=2020. National policies for paediatric universal BCG vaccination were associated with decreased mortality due to COVID-19.|pdf=|usr=010}}
+
−
{{tp|p=32557955|t=2020. Targeting the interleukin-17 pathway to prevent acute respiratory distress syndrome associated with SARS-CoV-2 infection.|pdf=|usr=010}}
+
−
{{tp|p=32571730|t=2020. Anakinra, una alternativa potencial en el tratamiento de la infeccion respiratoria grave por SARS-CoV-2 refractaria a tocilizumab.|pdf=|usr=010}}
+
−
{{tp|p=32579014|t=2020. Systemic inflammatory response and thrombosis due to alterations in the gut microbiota in COVID-19.|pdf=|usr=010}}
+
−
{{tp|p=32579012|t=2020. COVID-19. Immunothrombosis and the gastrointestinal tract.|pdf=|usr=010}}
+
−
{{tp|p=32558210|t=2020. Clearance of chloroquine and hydroxychloroquine by the Seraph(R) 100 Microbind(R) Affinity blood filter - approved for the treatment of COVID-19 patients.|pdf=|usr=010}}
+
−
{{tp|p=32568026|t=2020. Targeting infectious Coronavirus Disease 2019 (COVID-19) with Artificial Intelligence (AI) applications: Evidence based opinion.|pdf=|usr=010}}
+
−
{{tp|p=32593196|t=2020. The Another Side of COVID-19 in Alzheimer's Disease Patients: Drug-Drug Interactions.|pdf=|usr=010}}
+
−
{{tp|p=32579043|t=2020. Is there any supportive evidence for low dose radiotherapy for COVID-19 pneumonia?|pdf=|usr=010}}
+
−
{{tp|p=32589449|t=2020. Current State of Research About Chinese Herbal Medicines (CHM) for the Treatment of Coronavirus Disease 2019 (COVID-19): A Scoping Review.|pdf=|usr=010}}
+
−
{{tp|p=32579021|t=2020. Meditation and Yoga Practices as Potential Adjunctive Treatment of SARS-CoV-2 Infection and COVID-19: A Brief Overview of Key Subjects.|pdf=|usr=010}}
+
−
{{tp|p=32591771|t=2020. The challenging pathway towards the identification of SARS-CoV-2/COVID-19 therapeutics.|pdf=|usr=010}}
+
−
{{tp|p=32556272|t=2020. Stopping lopinavir/ritonavir in COVID-19 patients: duration of the drug interacting effect.|pdf=|usr=010}}
+
−
{{tp|p=32586154|t=2020. Montelukast's ability to fight COVID-19 infection.|pdf=|usr=010}}
+
−
{{tp|p=32583729|t=2020. Immunoinformatics study to search epitopes of spike glycoprotein from SARS-CoV-2 as potential vaccine.|pdf=|usr=010}}
+
−
{{tp|p=32579065|t=2020. Binding insight of clinically oriented drug famotidine with the identified potential target of SARS-CoV-2.|pdf=|usr=010}}
+
−
{{tp|p=32579064|t=2020. In-silico investigation of phytochemicals from Asparagus racemosus as plausible antiviral agent in COVID-19.|pdf=|usr=010}}
+
−
{{tp|p=32579061|t=2020. Pharmacoinformatics and molecular dynamics simulation studies reveal potential covalent and FDA-approved inhibitors of SARS-CoV-2 main protease 3CL(pro).|pdf=|usr=010}}
+
−
{{tp|p=32579059|t=2020. Screening of Chloroquine, Hydroxychloroquine and its derivatives for their binding affinity to multiple SARS-CoV-2 protein drug targets.|pdf=|usr=010}}
+
−
{{tp|p=32573355|t=2020. Targeting SARS-COV-2 non-structural protein 16: a virtual drug repurposing study.|pdf=|usr=010}}
+
−
{{tp|p=32573351|t=2020. Ethnomedicines of Indian origin for combating COVID-19 infection by hampering the viral replication: using structure-based drug discovery approach.|pdf=|usr=010}}
+
−
{{tp|p=32571168|t=2020. Drug repurposing against SARS-CoV-2 using E-pharmacophore based virtual screening, molecular docking and molecular dynamics with main protease as the target.|pdf=|usr=010}}
+
−
{{tp|p=32568620|t=2020. Remdesivir (GS-5734) as a therapeutic option of 2019-nCOV main protease - in silico approach.|pdf=|usr=010}}
+
−
{{tp|p=32568618|t=2020. Chemical-informatics approach to COVID-19 drug discovery: Monte Carlo based QSAR, virtual screening and molecular docking study of some in-house molecules as papain-like protease (PLpro) inhibitors.|pdf=|usr=010}}
+
−
{{tp|p=32568613|t=2020. Evaluation of green tea polyphenols as novel corona virus (SARS CoV-2) main protease (Mpro) inhibitors - an in silico docking and molecular dynamics simulation study.|pdf=|usr=010}}
+
−
{{tp|p=32568013|t=2020. Virtual screening and dynamics of potential inhibitors targeting RNA binding domain of nucleocapsid phosphoprotein from SARS-CoV-2.|pdf=|usr=010}}
+
−
{{tp|p=32568012|t=2020. Sars-cov-2 host entry and replication inhibitors from Indian ginseng: an in-silico approach.|pdf=|usr=010}}
+
−
{{tp|p=32567995|t=2020. Promising inhibitors of main protease of novel corona virus to prevent the spread of COVID-19 using docking and molecular dynamics simulation.|pdf=|usr=010}}
+
−
{{tp|p=32567989|t=2020. In silico identification of potential inhibitors from Cinnamon against main protease and spike glycoprotein of SARS CoV-2.|pdf=|usr=010}}
+
−
{{tp|p=32567979|t=2020. Structure-based virtual screening and molecular dynamics simulation of SARS-CoV-2 Guanine-N7 methyltransferase (nsp14) for identifying antiviral inhibitors against COVID-19.|pdf=|usr=010}}
+
−
{{tp|p=32567501|t=2020. Constituents of buriti oil (Mauritia flexuosa L.) like inhibitors of the SARS-Coronavirus main peptidase: an investigation by docking and molecular dynamics.|pdf=|usr=010}}
+
−
{{tp|p=32567487|t=2020. nCOV-19 peptides mass fingerprinting identification, binding, and blocking of inhibitors flavonoids and anthraquinone of Moringa oleifera and hydroxychloroquine.|pdf=|usr=010}}
+
−
{{tp|p=32568969|t=2020. Pharmacological development of the potential adjuvant therapeutic agents against coronavirus disease 2019.|pdf=|usr=010}}
+
−
{{tp|p=32579707|t=2020. Clinical pharmacology considerations for developing small molecule treatments for COVID-19.|pdf=|usr=010}}
+
−
{{tp|p=32571115|t=2020. Cutaneous side effects of hydroxychloroquine in health care workers in a COVID referral hospital - implications for clinical practice.|pdf=|usr=010}}
+
−
{{tp|p=32538738|t=2020. Molecular simulation of SARS-CoV-2 spike protein binding to pangolin ACE2 or human ACE2 natural variants reveals altered susceptibility to infection.|pdf=|usr=010}}
+
−
{{tp|p=32584243|t=2020. Empiric Therapies for COVID-19: Destined to Fail by Ignoring the Lessons of History.|pdf=|usr=010}}
+
−
{{tp|p=32591393|t=2020. A Potently Neutralizing Antibody Protects Mice against SARS-CoV-2 Infection.|pdf=|usr=010}}
+
−
{{tp|p=32559452|t=2020. Hydroxychloroquine use in COVID-19: what is the basis for baseline tests?|pdf=|usr=010}}
+
−
{{tp|p=32559419|t=2020. Therapeutic blockade of granulocyte macrophage colony-stimulating factor in COVID-19-associated hyperinflammation: challenges and opportunities.|pdf=|usr=010}}
+
−
{{tp|p=32546047|t=2020. Ig-like ACE2 protein therapeutics: A revival in development during the COVID-19 pandemic.|pdf=|usr=010}}
+
−
{{tp|p=32574572|t=2020. Letter to the editor: Immunomodulation by phsphodiesterase-4 inhibitor in COVID-19 patients.|pdf=|usr=010}}
+
−
{{tp|p=32579258|t=2020. Antiviral activities of mycophenolic acid and IMD-0354 against SARS-CoV-2.|pdf=|usr=010}}
+
−
{{tp|p=32578354|t=2020. Obesity and COVID-19: The mTOR pathway as a possible culprit.|pdf=|usr=010}}
+
−
{{tp|p=32554811|t=2020. Infant With SARS-CoV-2 Infection Causing Severe Lung Disease Treated With Remdesivir.|pdf=|usr=010}}
+
−
{{tp|p=32588453|t=2020. Covid-19 and Thymoquinone: Connecting the Dots.|pdf=|usr=010}}
+
−
{{tp|p=32552307|t=2020. A rationale for blocking thromboinflammation in COVID-19 with Btk inhibitors.|pdf=|usr=010}}
+
−
{{tp|p=32564047|t=2020. Chloroquine in controlling biological infections.|pdf=|usr=010}}
+
−
{{tp|p=32569363|t=2020. Outcomes in Patients with Severe COVID-19 Disease Treated with Tocilizumab - A Case- Controlled Study.|pdf=|usr=010}}
+
−
{{tp|p=32584474|t=2020. A brief review of interplay between vitamin D and angiotensin-converting enzyme 2: Implications for a potential treatment for COVID-19.|pdf=|usr=010}}
+
−
{{tp|p=32568376|t=2020. Successful treatment of severe COVID-19 with subcutaneous anakinra as a sole treatment.|pdf=|usr=010}}
+
−
{{tp|p=32556278|t=2020. Real-life experience of tocilizumab use in COVID-19 patients.|pdf=|usr=010}}
+
−
{{tp|p=32543892|t=2020. Development of a simple, interpretable and easily transferable QSAR model for quick screening antiviral databases in search of novel 3C-like protease (3CLpro) enzyme inhibitors against SARS-CoV diseases.|pdf=|usr=010}}
+
−
{{tp|p=32590699|t=2020. ACTH 1-24 and other melanocortins for COVID-19 treatment.|pdf=|usr=010}}
+
−
{{tp|p=32585765|t=2020. A Case of Successful Treatment of Severe COVID-19 Pneumonia with Favipiravir and Tocilizumab in Post-kidney Transplant Recipient.|pdf=|usr=010}}
+
−
{{tp|p=32573990|t=2020. Heart Transplant Recipient Patient with COVID-19 Treated with Tocilizumab.|pdf=|usr=010}}
+
−
{{tp|p=32584762|t=2020. [Rationales for using JAK 1/2 inhibitors in severely afflicted patients with COVID-19 pneumonia].|pdf=|usr=010}}
+
−
{{tp|p=32591367|t=2020. Is the production of a Covid-19 vaccine using transformed Pasteurella plausible?|pdf=|usr=010}}
+
−
{{tp|p=32542847|t=2020. Clinical use of Convalescent Plasma in the COVID-19 pandemic; a transfusion-focussed gap analysis with recommendations for future research priorities.|pdf=|usr=010}}
+

Version vom 3. Oktober 2020, 20:18 Uhr

coviki.org collects the really good Ideas and the scientific Record on Covid-19 Virus.

 P further streaming-in related content is here

...so calm down and enjoy the progress of immediate translational medicine: 

A concept of curative retargeting has been found by cellular lockdown with kinase inhibitors from the oncologic pharmacopoiea.
This means, virus replication can be stalled to zero w/o need of develpoment of new substances. There is no need for world
vaccination anymore. The virus needs permissible cells, and most perimissible is phosphotyrosine on its own compnents.
Paper is (not yet in PubMed) :

credentials to Marinus Brandl who told us about it today. based on e.g.

32408336 2020. Proteomics of SARS-CoV-2-infected host cells reveals therapy targets 
=======================================================================================

COVID19 is now a CURABLE disease !!!

=======================================================================================




Von „http://coviki.org/cov/index.php?title=Candidate_Compounds_Covid19&oldid=27444“
Meine Werkzeuge
Namensräume
Varianten
Aktionen
Navigation
Werkzeuge
Blogverzeichnis - Blog Verzeichnis bloggerei.deBlogverzeichnis